Hard-hit Novo Nordisk still has M&A ‘on the radar’ post-Ablynx setback, CEO says

Let’s just say it hasn’t been a great week for Novo Nordisk. After losing out to higher bidder Sanofi on a buyout of Ablynx, the Danish drugmaker Thursday rolled out fourth-quarter results and 2018 guidance that Oddo BHF analyst Sebastien Malafosse called “disappointing” in a note to clients.Original Article